Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Divyadeep Karumanchi"'
Autor:
Paola Guglielmelli, Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Minghui Duan, Haitao Meng, Ling Pan, Guangsheng He, Srdan Verstovsek, Françoise Boyer, Fiorenza Barraco, Dietger Niederwieser, Ester Pungolino, Anna Marina Liberati, Claire Harrison, Pantelia Roussou, Monika Wroclawska, Divyadeep Karumanchi, Karen Sinclair, Peter A.W. te Boekhorst, Heinz Gisslinger
Publikováno v:
Therapeutic Advances in Hematology, Vol 13 (2022)
Background: Thrombocytopenia is a common feature of myelofibrosis (MF), a myeloproliferative neoplasm driven by dysregulated JAK/STAT signaling; however, pivotal trials assessing the efficacy of ruxolitinib (a JAK1/2 inhibitor) excluded MF patients w
Externí odkaz:
https://doaj.org/article/d9a8c4a6c15d4398ace68f263124dc8d
Autor:
Raoul Herbrecht, Robert Pack, Monika Wroclawska, Rüdiger Liersch, Burkhard Schmidt, Fiorenza Barraco, Heinz Gisslinger, Reinier Raymakers, Andreas Reiter, Richard Greil, Divyadeep Karumanchi, Wolfgang Willenbacher, Karin Burock
Publikováno v:
British Journal of Haematology. 191:764-774
Primary objective of this non-interventional, post-authorisation safety study was to provide real-world safety data [incidence of adverse drug reactions (ADRs)/serious adverse events (SAEs)] on adult patients with myelofibrosis exposed/or not exposed